What question did this study set out to answer?

To evaluate whether continuous or weekly adjuvant anthracycline and taxane schedules improve outcomes compared to standard two-week regimens in high-risk early-stage breast cancer.

November 25, 2014Journal of Clinical OncologyOpen Access

SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

GBG. Thomas BuddCleveland Clinic WBWilliam E. BarlowCancer Research And Biostatistics HMHalle C. F. MooreCleveland Clinic

Discussion

Member takes

Implication

Randomized trial demonstrates equivalent disease-free survival across chemotherapy schedules in early-stage breast cancer, suggesting every-two-week dosing optimizes overall survival.

Key Points

To evaluate whether continuous or weekly adjuvant anthracycline and taxane schedules improve outcomes compared to standard two-week regimens in high-risk early-stage breast cancer.
Conducted a 2 × 2 factorial randomized phase III trial evaluating continuous vs. every-2-week doxorubicin-cyclophosphamide and weekly vs. every-2-week paclitaxel in 2,716 patients with node-positive or high-risk node-negative early breast cancer.
Tracked disease-free survival as the primary endpoint and overall survival as a secondary endpoint over a median follow-up of 6 years.
Interim analysis crossed futility boundaries for superiority, revealing a significant interaction between the two randomization factors for disease-free survival (P = .024) and overall survival (P = .010).
Comparison of all four arms showed no significant difference in disease-free survival (P = .11), but demonstrated a significant difference in overall survival (P = .040), favoring treatment given every 2 weeks.
The overall survival advantage for every-2-week dosing was concentrated in hormone receptor-negative/HER2-negative tumors (P = .067), with no differences observed in HR-positive/HER2-negative (P = .90) or HER2-positive tumors (P = .40).

Cite This Study

Budd et al. (2014) studied this question.

synapsesocial.com/papers/6a6cd606febe604dd7079a81 https://doi.org/10.1200/jco.2014.56.3296

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates equivalent disease-free survival across chemotherapy schedules in early-stage breast cancer, suggesting every-two-week dosing optimizes overall survival.

SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider